BIBN 99

BIBN 99
Names
	IUPAC name N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide
Identifiers
CAS Number	145301-48-0;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL4468100;
ChemSpider	117150;
PubChem CID	132712;
CompTox Dashboard (EPA)	DTXSID00162975 ;
	InChI Key: LUPAFPUKESJDMZ-UHFFFAOYSA-N; InChI=1S/C31H42ClN5O3/c1-5-15-31(3,4)30(40)36(6-2)17-8-9-22-13-18-35(19-14-22)21-27(38)37-26-12-11-23(32)20-24(26)29(39)34-25-10-7-16-33-28(25)37/h7,10-12,16,20,22H,5-6,8-9,13-15,17-19,21H2,1-4H3,(H,34,39);
	SMILES CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=C(C=C(C=C3)Cl)C(=O)NC4=C2N=CC=C4;
Properties
Chemical formula	C31H42ClN5O3
Molar mass	568.16 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

BIBN 99 is an antagonist of mACh receptors. Specifically, it is selective for the M2 type.^[1]

Effects

During research, it was observed that BIBN 99 was able to diminish the cognitive deficits caused by injury.^[2] Another also came to the conclusion that the compound could provide cognitive improvements.^[3] The cognitive effects could possibly be caused by the increased release of acetylcholine, a neurotransmitter.^[4]

References

^ Doods, H.; Entzeroth, M.; Ziegler, H.; Schiavi, G.; Engel, W.; Mihm, G.; Rudolf, K.; Eberlein, W. (1993-09-21). "Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist". European Journal of Pharmacology. 242 (1): 23–30. doi:10.1016/0014-2999(93)90005-3. ISSN 0014-2999. PMID 8223934.
^ Pike, B. R.; Hamm, R. J. (1995-07-17). "Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats". Brain Research. 686 (1): 37–43. doi:10.1016/0006-8993(95)00448-y. ISSN 0006-8993. PMID 7583269.
^ Rowe, W. B.; O'Donnell, J.-P.; Pearson, D.; Rose, G. M.; Meaney, M. J.; Quirion, R. (2003-10-17). "Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats". Behavioural Brain Research. 145 (1–2): 171–178. doi:10.1016/s0166-4328(03)00116-5. ISSN 0166-4328. PMID 14529815.
^ Quirion, R.; Wilson, A.; Rowe, W.; Aubert, I.; Richard, J.; Doods, H.; Parent, A.; White, N.; Meaney, M. J. (February 1995). "Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired". The Journal of Neuroscience. 15 (2): 1455–1462. doi:10.1523/JNEUROSCI.15-02-01455.1995. ISSN 0270-6474. PMC 6577836. PMID 7869110.

[1] Doods, H.; Entzeroth, M.; Ziegler, H.; Schiavi, G.; Engel, W.; Mihm, G.; Rudolf, K.; Eberlein, W. (1993-09-21). "Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist". European Journal of Pharmacology. 242 (1): 23–30. doi:10.1016/0014-2999(93)90005-3. ISSN 0014-2999. PMID 8223934.

[2] Pike, B. R.; Hamm, R. J. (1995-07-17). "Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats". Brain Research. 686 (1): 37–43. doi:10.1016/0006-8993(95)00448-y. ISSN 0006-8993. PMID 7583269.

[3] Rowe, W. B.; O'Donnell, J.-P.; Pearson, D.; Rose, G. M.; Meaney, M. J.; Quirion, R. (2003-10-17). "Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats". Behavioural Brain Research. 145 (1–2): 171–178. doi:10.1016/s0166-4328(03)00116-5. ISSN 0166-4328. PMID 14529815.

[4] Quirion, R.; Wilson, A.; Rowe, W.; Aubert, I.; Richard, J.; Doods, H.; Parent, A.; White, N.; Meaney, M. J. (February 1995). "Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired". The Journal of Neuroscience. 15 (2): 1455–1462. doi:10.1523/JNEUROSCI.15-02-01455.1995. ISSN 0270-6474. PMC 6577836. PMID 7869110.

[1]

[2]

[3]

[4]